title: Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy.
abstract: Rhenium-188 (Re-188) is a high energy β-emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy γ-emission, which could be detected by γ-cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the β-emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.
authors: 1st Radiology Department, National & Kapodistrian University of Athens, Athens, Greece.
authors: Maria
authors: M
authors: Argyrou
authors: Alexia
authors: A
authors: Valassi
authors: Maria
authors: M
authors: Andreou
authors: Maria
authors: M
authors: Lyra
references: Nucl Med Biol. 2002 Jan;29(1):13-8
references: 11786271
references: Eur J Nucl Med. 1998 Jun;25(6):613-21
references: 9618576
references: J Nucl Med. 1999 Jan;40(1):11S-36S
references: 9935083
references: Nucl Med Commun. 2004 Oct;25(10):1007-13
references: 15381868
references: J Nucl Med. 1996 Mar;37(3):538-46
references: 8772664
references: Int J Mol Imaging. 2012;2012:278306
references: 22518301
references: J Nucl Med. 1998 Apr;39(4):659-63
references: 9544677
references: Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):542-6
references: 14691613
references: Nucl Med Commun. 2004 Jul;25(7):691-9
references: 15208496
references: Semin Nucl Med. 2008 Mar;38(2):S19-29
references: 18243839
references: Arch Med Res. 2008 Jan;39(1):100-9
references: 18068002
references: Nucl Med Commun. 2006 Mar;27(3):223-9
references: 16479241
references: Q J Nucl Med Mol Imaging. 2009 Jun;53(3):305-10
references: 19521309
references: Br J Cancer. 2003 Aug 18;89(4):625-9
references: 12915868
references: BMC Nucl Med. 2001;1(1):2
references: 11734069
references: J Nucl Med. 2005 Jun;46(6):1023-7
references: 15937315
references: J Nucl Med. 2011 Nov;52(11):1721-6
references: 21976530
references: J Clin Oncol. 2003 Aug 1;21(15):2869-75
references: 12885803
references: Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1934-40
references: 18649080
references: J Nucl Med. 2005 Jan;46(1):60-6
references: 15632035
references: Nat Med. 2000 Aug;6(8):859-60
references: 10932214
references: J Nucl Med. 2003 Jun;44(6):953-60
references: 12791825
references: Appl Radiat Isot. 2000 Jan;52(1):63-8
references: 10670924